Oncotarget

Clinical Research Papers:

Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study

Hai-Liang Zhang _, Xiao-Jian Qin, Hong-Kai Wang, Wei-Jie Gu, Chun-Guang Ma, Guo-Hai Shi, Liang-Ping Zhou and Ding-Wei Ye

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:36870-36883. https://doi.org/10.18632/oncotarget.4874

Metrics: PDF 2283 views  |   HTML 959 views  |   ?  


Abstract

Hai-Liang Zhang1,2,*, Xiao-Jian Qin1,2,*, Hong-Kai Wang1,2, Wei-Jie Gu1,2, Chun-Guang Ma1,2, Guo-Hai Shi1,2, Liang-Ping Zhou2,3, Ding-Wei Ye1,2

1Department of Urology, Fudan University, Shanghai Cancer Center, Shanghai 200032, P.R. China

2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China

3Department of Radiology, Fudan University, Shanghai Cancer Center, Shanghai 200032, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Ding-Wei Ye, e-mail: wyeli@163.com

Keywords: sorafenib, advanced RCC, China, overall survival, prognostic factors

Received: May 08, 2015     Accepted: October 01, 2015     Published: October 14, 2015

ABSTRACT

Data on long-term survival and prognostic significance of demographic factors and adverse events (AEs) associated with sorafenib, an orally administered multikinase inhibitor in Chinese population with advanced renal cell carcinoma (RCC) are limited. Outcome data from adult patients (n = 256) with advanced RCC who received sorafenib (400 mg twice daily) either as first-line or second-line therapy between April 2006 and May 2013 were analyzed retrospectively. The primary endpoint was median overall survival (OS), determined to be 22.2 (95% CI: 17.1–27.4) months, and the secondary endpoint was overall median progression-free survival (PFS), determined to be 13.6 (95% CI: 10.7–16.4) months at a median follow-up time of 61.8 (95% CI: 16.2–97.4) months. Analysis of the incidence of AEs revealed the most common side effect as hand-foot skin reactions (60.5%) followed by diarrhea (38.7%), fatigue (35.5%), alopecia (34.0%), rash (24.6%), hypertension (21.5%) and gingival hemorrhage (21.1%). Multivariate regression analysis revealed older age (≥ 58 years), lower Memorial Sloan-Kettering Cancer Center score, time from nephrectomy to sorafenib treatment, number of metastatic tumors and best response as significant and independent demographic predictors for improved PFS and/or OS (p ≤ 0.05). Alopecia was identified as a significant and independent predictor of increased OS, whereas vomiting and weight loss were identified as significant predictors of decreased OS (p ≤ 0.05). Sorafenib significantly improved OS and PFS in Chinese patients with advanced RCC. Considering the identified significant prognostic demographic factors along with the advocated prognostic manageable AEs while identifying treatment strategy may help clinicians select the best treatment modality and better predict survival in these patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4874